# To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer

Source: https://onco.cc/trials/nct06504732/  
OnCo record `nct06504732` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial testing IAH0968 in gastric & gastro-oesophageal junction cancer, now recruiting.

## Summary

To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer is a phase 2/3 interventional study registered as NCT06504732, led by SUNHO（China）BioPharmaceutical CO., and recruiting on the registry. Official title: A Phase II/III Clinical Study Evaluating IAH0968 in Combination or Not in Combination With the CAPEOX Regimen in HER2-expressing Advanced/Metastatic Solid Tumours and Gastric Cancer. Planned enrolment is 574 participants (estimated). The study started in 2024-08-15 and primary completion is expected in 2028-07. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT06504732
- Phase: 2/3
- Setting: A Phase II/III Clinical Study Evaluating IAH0968 in Combination or Not in Combination With the CAPEOX Regimen in HER2-expressing Advanced/Metastatic Solid Tumors and Gastric Cancer
- Sponsor: SUNHO（China）BioPharmaceutical CO.
- Enrolled: 574

## Sources

- ClinicalTrials.gov NCT06504732: https://clinicaltrials.gov/study/NCT06504732

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [HER2-positive gastric cancer](https://onco.cc/cancers/gastric-her2-positive/)
- drugs: [IAH0968](https://onco.cc/drugs/iah0968/)
- companies: [Hutchmed](https://onco.cc/companies/hutchmed/), [SunHo Biopharmaceutical](https://onco.cc/companies/sunho-biopharmaceutical/)

---
JSON: https://onco.cc/api/v1/entities/nct06504732.json